Kymera Therapeutics, Inc.
NASDAQ:KYMRBiotechnology
+$1.50 today
- Market cap
- $10.34B
- Beta
- 2.03
- P/E (TTM)
- -28.3
- EPS (TTM)
- -$3.23
Volume 0.68M
Average 0.58M
KYMR Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Kymera Therapeutics, Inc.NASDAQ: KYMR
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization dips below year-ago levels
Q2 FY2026 depreciation & amortization of $2.03M fell 2.6% year over year, behind the +1.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 0.4% from the prior quarter. Over 3 fiscal years it compounded at +40.8% a year.
Context
- Depreciation & amortization amounted to 21.2% of revenue in FY2025, up 5.5 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -2.6% toward the trailing-twelve-month pace of +1.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 8.31M USD
- Year-over-year change
- +12.7%
- 4-year CAGR
- +36.5%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.31M | +12.7% |
| FY2024 | 2024-12-31 | 7.37M | +106.8% |
| FY2023 | 2023-12-31 | 3.57M | +19.8% |
| FY2022 | 2022-12-31 | 2.98M | +24.2% |
| FY2021 | 2021-12-31 | 2.4M | — |
Depreciation & Amortization vs competitors
How KYMR compares with its peers on the latest reported figures
- KYMR's LTM Jun 2026 depreciation & amortization of $8.23M is the 3rd highest of the 5 companies compared; the peer median is $6.42M.
- Its year-over-year change of +1.6% is the highest of 5, against a peer median of -21.7%.
- Depreciation & amortization amounts to 7.8% of revenue for KYMR, versus a peer median of 7.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Aug 2026 | $14.4M | -22.3% | +20.4% | 2.1% | |
| LTM Mar 2026 | $8.34M | +0.8% | +30.7% | 19.4% | |
| LTM Jun 2026 | $8.23M | +1.6% | +40.8% | 7.8% | |
| LTM Mar 2026 | $4.5M | -21.1% | -14.1% | 5.0% | |
| LTM Mar 2026 | $3.3M | -47.7% | +5.3% | 9.5% | |
| Peer median (excluding KYMR) | $6.42M | -21.7% | +12.9% | 7.3% | |
Competitors are the stored peer set for KYMR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 72.83M | 46.83M | 78.59M | 47.07M | 39.2M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 72.83M | 46.83M | 78.59M | 47.07M | 39.2M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 137.02M | 164.25M | 189.08M | 240.25M | 316.6M |
| Selling, General & Admin | 36.35M | 43.83M | 55.04M | 63.53M | 68.2M |
| Operating Expenses | 173.36M | 208.08M | 244.12M | 308.71M | 388.6M |
| Depreciation & Amortization | 2.4M | 2.98M | 3.57M | 7.37M | 8.31M |
| EBITDA | (97.65M) | (151.66M) | (143.2M) | (216.24M) | (303.06M) |
| EBITDA Margin | -134.1% | -323.9% | -182.2% | -459.4% | -773.1% |
| Operating Income | (100.53M) | (161.26M) | (165.53M) | (261.64M) | (349.4M) |
| Operating Margin | -138.0% | -344.4% | -210.6% | -555.8% | -891.3% |
| Interest Income | 488K | 6.62M | 18.76M | 38.03M | 38.03M |
| Interest Expense | 175K | 176K | 196K | 249K | 249K |
| Other Income / Expenses | 313K | 6.45M | 18.57M | 37.78M | 37.78M |
| Income Before Tax | (100.22M) | (154.81M) | (146.96M) | (223.86M) | (311.62M) |
| Pre-Tax Margin | -137.6% | -330.6% | -187.0% | -475.6% | -795.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (100.22M) | (154.81M) | (146.96M) | (223.86M) | (311.4M) |
| Net Margin | -137.6% | -330.6% | -187.0% | -475.6% | -794.4% |
| EPS (Basic) | (2.09) | (2.87) | (2.52) | (2.98) | (3.69) |
| EPS (Diluted) | (2.09) | (2.87) | (2.52) | (2.98) | (3.69) |
| Weighted Avg Shares | 47.99M | 53.93M | 58.37M | 75.04M | 84.39M |
| Weighted Avg Shares (Diluted) | 47.99M | 53.93M | 58.37M | 75.04M | 84.39M |
Kymera Therapeutics, Inc.
NASDAQ:KYMR
Intrinsic Alpha fair value
Locked
Current Price
$121.13
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.